Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antibody Drug Conjugates Market

Antibody Drug Conjugates Market Trends

Report ID: GMI5940
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Antibody Drug Conjugates Market Trends

Increasing prevalence of cancer worldwide have significantly created the demand for effective and targeted treatment options. Antibody drug conjugate offers unique approach by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs, intended to target and kill tumor cells while minimizing damage to healthy cells. Also, ADCs possess the potential to overcome drug resistance mechanisms observed in cancer cells, thereby increasing the effectiveness of treatment. Furthermore, antibody drug conjugate can be utilized in combination therapies and personalized medicine that allows patient specific treatment that aids to attain improved patient outcomes and enhance the patient quality of life.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for antibody drug conjugates was USD 7.7 billion in 2023 and will witness a 14.8% CAGR from 2024 to 2032.

The cleavable linker segment will surpass USD 14.3 billion by 2032 as to significant advancements in antibody-drug conjugates that enable to release of the cytotoxic payload specifically within cancer cells, thereby enhancing treatment efficacy.

North America market share for antibody drug conjugates was over 49.5% in 2022 owing to the increasing prevalence of cancer and the growing demand for targeted therapies in the region.

Seagen Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc among others.